Patient Experience Technology Market worth $1.29 billion by 2031 - Exclusive Report by MarketsandMarkets™

The global patient experience technology market is projected to grow from $0.74 billion in 2026 to $1.29 billion by 2031, representing an 11.8% CAGR, driven by AI-enabled communication, digital patient portals, virtual care and integrated engagement platforms. Software represented 67.9% of the market in 2025, while healthcare providers accounted for 67.7%; Asia-Pacific and healthcare payers are expected to post the fastest growth. Industry consolidation is accelerating, highlighted by Qualtrics' completed $6.75 billion acquisition of Press Ganey Forsta in May 2026, as vendors seek healthcare data, AI capabilities and end-to-end patient journey platforms.

Analysis

This is a strategic validation signal rather than a material near-term TAM revision for listed names. The addressable revenue pool remains too small to move ORCL, CRM, NICE, IQV, or TWLO at the consolidated level; their relevant upside is indirect, through higher attach rates to EHR, contact-center, CRM, and data-cloud deployments. The more investable implication is that hospital buyers are consolidating point solutions, raising switching costs for vendors embedded in workflow and compressing the long-tail of standalone survey, messaging, and scheduling vendors.

HCAT and PHR have the clearest potential revenue sensitivity, but the economics differ. HCAT can use patient-engagement capabilities to improve retention and expand its analytics suite into provider operating budgets, although a meaningful rerating requires evidence that cross-sell offsets implementation costs and elongated hospital IT sales cycles. PHR is better positioned if digital-front-door spending translates into higher appointment conversion and transaction volumes; its risk is that EHR incumbents and provider-owned platforms bundle adjacent scheduling and communications functions at lower incremental price.

NRC is strategically exposed in both directions: its healthcare-specific benchmark data is valuable to an acquirer or a broader platform seeking differentiated training and workflow data, but agentic-AI tools could commoditize basic feedback collection and reduce seat-level pricing. The contrarian view is that investors may overvalue AI labels before providers demonstrate ROI through lower no-show rates, labor savings, or value-based-care quality scores. Over the next 1-3 months, earnings commentary on net retention, implementation duration, and AI attach rates matters more than third-party market-growth forecasts; over 6-18 months, consolidation should favor vendors with proprietary healthcare data and deeply integrated distribution.

Key Decisions for Investors

• Maintain a 6-12 month watch-list long bias toward HCAT, not a new position solely on this release. Initiate only if the next earnings call shows engagement-product cross-sell, stable or improving gross margin, and no deterioration in provider bookings; falsify on a guidance cut or material rise in implementation-related costs.
• Prefer PHR over TWLO as a targeted digital-patient-engagement exposure for the next 2-3 quarters. PHR has direct transaction-volume leverage to provider adoption, while TWLO's healthcare opportunity is unlikely to be large enough to overcome broader messaging-price and competition risk; use relative-performance stops if PHR underperforms TWLO by 10% after results.
• Monitor NRC for strategic-value optionality rather than chase near-term AI enthusiasm. A credible acquisition, partnership, or evidence of AI-enabled pricing expansion could justify a position; absent that, recurring-revenue growth below management expectations would indicate that platform consolidation is benefiting larger workflow incumbents instead.
• Do not add ORCL, CRM, NICE, or IQV on this theme alone. Treat positive healthcare AI bookings, EHR/CRM attachment disclosures, or payer-specific contract wins as required catalysts; the likely earnings impact is immaterial relative to their existing revenue bases.